BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 12888588)

  • 1. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
    J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
    Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
    Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis treatment, Italy.
    Gradoni L; Gramiccia M; Scalone A
    Emerg Infect Dis; 2003 Dec; 9(12):1617-20. PubMed ID: 14720406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
    Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
    J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
    Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
    Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
    Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
    Shahian M; Alborzi A
    Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).
    Pagliano P; Rossi M; Rescigno C; Altieri S; Coppola MG; Gramiccia M; Scalone A; Gradoni L; Faella F
    J Antimicrob Chemother; 2003 Aug; 52(2):264-8. PubMed ID: 12865389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
    Amato VS; Tuon FF; Campos A; Bacha HA; Nicodemo AC; Amato Neto V; Shikanai-Yasuda MA
    Clin Infect Dis; 2007 Jan; 44(2):311-2. PubMed ID: 17173238
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
    Gradoni L; Gramiccia M; Scalone A
    Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.